Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Dnase1L3 Regulates Inflammasome-Dependent Cytokine Secretion.

Shi G, Abbott KN, Wu W, Salter RD, Keyel PA.

Front Immunol. 2017 May 8;8:522. doi: 10.3389/fimmu.2017.00522. eCollection 2017.

2.

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foster PJ, Gaudet J, Gariepy J, Sekaly RP, Lacombe L, Fradet Y, Foley R.

Cancer Immunol Res. 2016 Oct;4(10):881-892. Epub 2016 Sep 7.

3.

CD40L induces functional tunneling nanotube networks exclusively in dendritic cells programmed by mediators of type 1 immunity.

Zaccard CR, Watkins SC, Kalinski P, Fecek RJ, Yates AL, Salter RD, Ayyavoo V, Rinaldo CR, Mailliard RB.

J Immunol. 2015 Feb 1;194(3):1047-56. doi: 10.4049/jimmunol.1401832. Epub 2014 Dec 29.

4.

Methylthioadenosine reprograms macrophage activation through adenosine receptor stimulation.

Keyel PA, Romero M, Wu W, Kwak DH, Zhu Q, Liu X, Salter RD.

PLoS One. 2014 Aug 12;9(8):e104210. doi: 10.1371/journal.pone.0104210. eCollection 2014.

5.

Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation.

Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD.

J Immunol. 2013 Nov 15;191(10):5230-8. doi: 10.4049/jimmunol.1301490. Epub 2013 Oct 2.

6.

Reduction of streptolysin O (SLO) pore-forming activity enhances inflammasome activation.

Keyel PA, Roth R, Yokoyama WM, Heuser JE, Salter RD.

Toxins (Basel). 2013 Jun 6;5(6):1105-18. doi: 10.3390/toxins5061105.

7.

The second transmembrane domain of P2X7 contributes to dilated pore formation.

Sun C, Heid ME, Keyel PA, Salter RD.

PLoS One. 2013 Apr 17;8(4):e61886. doi: 10.1371/journal.pone.0061886. Print 2013.

8.

Visualization of bacterial toxin induced responses using live cell fluorescence microscopy.

Keyel PA, Heid ME, Watkins SC, Salter RD.

J Vis Exp. 2012 Oct 1;(68):e4227. doi: 10.3791/4227.

9.

Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation.

Keyel PA, Tkacheva OA, Larregina AT, Salter RD.

J Immunol. 2012 Nov 1;189(9):4621-9. doi: 10.4049/jimmunol.1200828. Epub 2012 Sep 26.

10.

Preventive immunization of aged and juvenile non-human primates to β-amyloid.

Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA.

J Neuroinflammation. 2012 May 3;9:84.

11.

Genetically encoded pH sensor for tracking surface proteins through endocytosis.

Grover A, Schmidt BF, Salter RD, Watkins SC, Waggoner AS, Bruchez MP.

Angew Chem Int Ed Engl. 2012 May 14;51(20):4838-42. doi: 10.1002/anie.201108107. Epub 2012 Mar 29.

12.

Large scale comparison of innate responses to viral and bacterial pathogens in mouse and macaque.

Zinman G, Brower-Sinning R, Emeche CH, Ernst J, Huang GT, Mahony S, Myers AJ, O'Dee DM, Flynn JL, Nau GJ, Ross TM, Salter RD, Benos PV, Bar Joseph Z, Morel PA.

PLoS One. 2011;6(7):e22401. doi: 10.1371/journal.pone.0022401. Epub 2011 Jul 18.

13.

Macrophage responses to bacterial toxins: a balance between activation and suppression.

Keyel PA, Heid ME, Salter RD.

Immunol Res. 2011 Aug;50(2-3):118-23. doi: 10.1007/s12026-011-8212-3. Review.

14.

Streptolysin O clearance through sequestration into blebs that bud passively from the plasma membrane.

Keyel PA, Loultcheva L, Roth R, Salter RD, Watkins SC, Yokoyama WM, Heuser JE.

J Cell Sci. 2011 Jul 15;124(Pt 14):2414-23. doi: 10.1242/jcs.076182. Epub 2011 Jun 21.

15.

Extracellular superoxide dismutase in macrophages augments bacterial killing by promoting phagocytosis.

Manni ML, Tomai LP, Norris CA, Thomas LM, Kelley EE, Salter RD, Crapo JD, Chang LY, Watkins SC, Piganelli JD, Oury TD.

Am J Pathol. 2011 Jun;178(6):2752-9. doi: 10.1016/j.ajpath.2011.02.007.

16.

Activation of macrophages by P2X7-induced microvesicles from myeloid cells is mediated by phospholipids and is partially dependent on TLR4.

Thomas LM, Salter RD.

J Immunol. 2010 Sep 15;185(6):3740-9. doi: 10.4049/jimmunol.1001231. Epub 2010 Aug 13.

17.

Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function.

Sun C, Chu J, Singh S, Salter RD.

Purinergic Signal. 2010 Mar;6(1):31-45. doi: 10.1007/s11302-009-9168-9. Epub 2009 Oct 17.

18.

WITHDRAWN: Communication between immune cells mediated by membrane connections.

Salter RD, Watkins SC.

Immunol Lett. 2009 Oct 4. [Epub ahead of print]

PMID:
19808050
19.

Dendritic cell altered states: what role for calcium?

Salter RD, Watkins SC.

Immunol Rev. 2009 Sep;231(1):278-88. doi: 10.1111/j.1600-065X.2009.00806.x. Review.

PMID:
19754904
20.

Cholesterol-dependent cytolysins induce rapid release of mature IL-1beta from murine macrophages in a NLRP3 inflammasome and cathepsin B-dependent manner.

Chu J, Thomas LM, Watkins SC, Franchi L, Núñez G, Salter RD.

J Leukoc Biol. 2009 Nov;86(5):1227-38. doi: 10.1189/jlb.0309164. Epub 2009 Aug 12.

21.

Dynamic properties of antigen uptake and communication between dendritic cells.

Salter RD, Watkins SC.

Immunol Res. 2006;36(1-3):211-20. Review.

PMID:
17337781
22.

Immunology in Pittsburgh.

Finn OJ, Salter RD.

Immunol Res. 2006;36(1-3):1-2.

PMID:
17337760
23.

Phagocytosis induces lysosome remodeling and regulated presentation of particulate antigens by activated dendritic cells.

Nayak JV, Hokey DA, Larregina A, He Y, Salter RD, Watkins SC, Falo LD Jr.

J Immunol. 2006 Dec 15;177(12):8493-503.

24.
25.

Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC.

Hu PQ, Tuma-Warrino RJ, Bryan MA, Mitchell KG, Higgins DE, Watkins SC, Salter RD.

J Immunol. 2004 Feb 1;172(3):1595-601.

26.

Rapid and extensive membrane reorganization by dendritic cells following exposure to bacteria revealed by high-resolution imaging.

Salter RD, Tuma-Warrino RJ, Hu PQ, Watkins SC.

J Leukoc Biol. 2004 Feb;75(2):240-3. Epub 2003 Nov 21.

PMID:
14634062
27.

BDCM: a novel B-cell line with genetic and functional similarity to dendritic cells.

Kharbanda S, Salter RD, Dong X, Tuma-Warrino RJ, Steinman RA.

Br J Haematol. 2002 Dec;119(3):819-25.

PMID:
12437665
28.

Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.

Jäger E, Höhn H, Necker A, Förster R, Karbach J, Freitag K, Neukirch C, Castelli C, Salter RD, Knuth A, Maeurer MJ.

Int J Cancer. 2002 Mar 20;98(3):376-88.

29.

Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.

Maeurer MJ, Necker A, Salter RD, Castelli C, Höhn H, Karbach J, Freitag K, Neukirch C, Knuth A, Jäger E.

Int J Cancer. 2002 Jan 1;97(1):64-71.

30.

Antigen recognition by T cells: a strong sense of structure.

Maeurer M, Höhn H, Castelli C, Salter RD, Necker A, Reichert T, Knuth A, Jäger E.

Trends Immunol. 2001 Nov;22(11):599-601. No abstract available.

PMID:
11698218
31.

Peptide-conformed beta2m-free class I heavy chains are intermediates in generation of soluble HLA by the membrane-bound metalloproteinase.

Demaria S, DeVito-Haynes LD, Salter RD, Burlingham WJ, Bushkin Y.

Hum Immunol. 1999 Dec;60(12):1216-26.

PMID:
10626735
32.

Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells.

Dong X, An B, Salvucci Kierstead L, Storkus WJ, Amoscato AA, Salter RD.

J Immunol. 2000 Jan 1;164(1):129-35.

33.

Immunotherapy of NOD mice with bone marrow-derived dendritic cells.

Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA.

Diabetes. 1999 Dec;48(12):2300-8.

PMID:
10580417
34.

Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells.

Dong X, Storkus WJ, Salter RD.

J Immunol. 1999 Nov 15;163(10):5427-34.

36.

The biosynthesis and secretion of prostate-specific antigen in LNCaP cells.

Gau JT, Salter RD, Krill D, Grove ML, Becich MJ.

Cancer Res. 1997 Sep 1;57(17):3830-4.

38.

Domain organization and sequence relationship of killer cell inhibitory receptors.

Salter RD, Chan HW, Tadikamalla R, Lawlor DA.

Immunol Rev. 1997 Feb;155:175-82. Review.

PMID:
9059893
39.

Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.

Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ.

Eur J Immunol. 1996 Nov;26(11):2613-23.

PMID:
8921947
41.
42.
43.

Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2.

Zeh HJ 3rd, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ.

Hum Immunol. 1994 Feb;39(2):79-86.

PMID:
8175386
45.

Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.

Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT.

J Immunol. 1993 Oct 1;151(7):3719-27.

PMID:
7690811
46.

Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.

Storkus WJ, Zeh HJ 3rd, Salter RD, Lotze MT.

J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):94-103.

PMID:
7506576
48.

Peptide-induced modulation of target cell sensitivity to natural killing.

Storkus WJ, Salter RD, Cresswell P, Dawson JR.

J Immunol. 1992 Aug 15;149(4):1185-90.

PMID:
1500711
49.

Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.

Newberg MH, Ridge JP, Vining DR, Salter RD, Engelhard VH.

J Immunol. 1992 Jul 1;149(1):136-42.

PMID:
1607650
50.

Role of endogenous peptide in human alloreactive cytotoxic T cell responses.

Man S, Salter RD, Engelhard VH.

Int Immunol. 1992 Mar;4(3):367-75.

PMID:
1373643

Supplemental Content

Loading ...
Support Center